XBiotech Inc.

XBIT

Explore Our Financial Data > Companies > XBiotech Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	XBIT
CIK	0001626878
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	5217 WINNEBAGO LANE, AUSTIN, TX, 78744
Website	xbiotech.com
Phone	512-386-2900
CEO	John Simard
Employees	100

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-39.44 million
Net Income	$-39.41 million
Net Income to Common	$-39.41 million
EPS	N/A

View All

Balance Sheet

Cash	$155.90 million
Assets	$181.86 million
Liabilities	$7.15 million
Common Equity	$174.71 million
Liabilities & Equity	$181.86 million

View All

Cash Flow Statement

Net Income	$-39.41 million
Cash From Operating Activities	$-30.48 million
Cash From Investing Activities	$-1.14 million
Cash From Financing Activities	$-9.86 million
Change in Cash	$-45.14 million

View All

Calculations

NOPAT	$-31.62 million
EBITDA	$-45.65 million
Price to Earnings	N/A
Price to Book	$0.52
ROE	-20.53%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

3 Promising Penny Stocks With Market Caps Above $90M

As the U.S. stock market navigates a landscape shaped by trade talks and economic data, investors are keenly watching for opportunities amid the shifting dynamics. Penny stocks, a term rooted in past market eras, continue to represent smaller or less-established companies that might offer significant value. By identifying those with strong financials and potential for growth, investors can uncover promising opportunities within this niche sector.

Article Link

Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Article Link

XBiotech: Q1 Earnings Snapshot

AUSTIN, Texas (AP) — XBiotech Inc. XBIT) on Wednesday reported a loss of $10.9 million in its first quarter. On a per-share basis, the Austin, Texas-based company said it had a loss of 36 cents.

Article Link

XBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35%

Key Insights Significant control over XBiotech by individual investors implies that the general public has more power...

Article Link

XBiotech Pauses Rheumatology program

Findings from recently completed Rheumatoid Arthritis Study raise questionsAUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently completed Phase II, Double-Blind, Placebo-Controlled, Randomized study in Rheumatoid Arthritis. The Phase II study failed to meet its primary endpoint amid substantial irregularities that make unequivocal

Article Link